Introduction {#sec1}
============

Species of *Providencia* are Gram-negative bacteria that belong to the *Enterobacteriaceae* family. Unlike many other bacteria of this family, species of *Providencia* are an infrequent cause of nosocomial infections. Among species of *Providencia, stuartii* and *rettgeri* are the most common causes of infections in hospitalized patients, mainly urinary tract infections. In addition to urinary tract infections, *P. stuartii* and *P. rettgeri* can cause pneumonia, meningitis, endocarditis, wound and bloodstream infections [@bib1], [@bib2], [@bib3]. Infections with species of *Providencia* have significant impact on patients\' morbidity, mortality and treatment [@bib4], [@bib5].

In 1904, the first species of *Providencia* was isolated by Rettger [@bib1]. At first the bacterium was noticed in chickens; it was believed to be an epidemic of fowl cholera. The bacterium was characterized in 1918, when it was named *Bacterium rettgerii* by Hadley *et al.* [@bib6]. In 1951, Kauffmann and Edwards [@bib7] first suggested the genus name *Providencia,* which included a cluster of microorganisms studied by Stuart and colleagues at Brown University in Providence, Rhode Island, USA. By 1983, *P. rettgeri, P. stuartii, P. alcalifaciens* and *P. rustigianii* were fully differentiated with urea hydrolyzation and DNA hybridization [@bib8]. In 1986, *P. heimbachae* was the fifth species discovered in the genus *Providencia* [@bib9].

Species of *Providencia* are non--lactose fermenting, methyl red and phenylpyruvic acid positive bacilli. Species of *Providencia* are positive for the phenylalanine deaminase test but negative for lysine decarboxylase, ornithine decarboxylase and arginine dihydrolase tests [@bib1]. Generally, they can be recognized by their fruity smell. Species of *Providencia* are commonly susceptible to carbapenems, amikacin, aztreonam, and second and third-generation cephalosporins including cefaclor, cefuroxime, cefetamet, cefpodoxime, ceftazidime, ceftriaxone and cefotaxime [@bib1]. Alternative choices for antimicrobial therapy include ciprofloxacin and cotrimoxazole [@bib1]. Species of *Providencia* are generally resistant to gentamicin, tobramycin, aminopenicillins and first-generation cephalosporins [@bib1]. *P. stuartii* and *P. rettgeri* can produce inducible AmpC β-lactamases [@bib10]. Moreover, plasmid-mediated resistance mechanisms such as extended-spectrum β-lactamases and metallo-β-lactamases have also been recovered from species of *Providencia* causing nosocomial infections [@bib11], [@bib12]. Unlike other Gram-negative bacteria (e.g. *Acinetobacter baumannii, Klebsiella pneumonia*), species of *Providencia* have intrinsic resistance to colistin and tigecycline, which makes treatment of the multidrug-resistant (MDR) strains of this pathogen challenging. Resistance can be transmissible from MDR *Providencia* species to other bacterial pathogens like susceptible strains of *Escherichia coli* and *vice versa* by transformation and conjugation [@bib11], [@bib13]. Carbapenem-resistant *Providencia* species are increasingly reported.

In this review, patients\' characteristics, resistance mechanisms, treatment and infection control measures of carbapenem-resistant *Providencia* species in the literature are described.

Methods {#sec2}
=======

We performed a nonsystematic narrative review about carbapenem-resistant *Providencia* species described in the literature. PubMed was searched using the following terms: (carbapenem) AND (resistant) AND (*Providencia*). The search returned 52 articles; all were screened for relevance to the subject of this review. Publications in languages other than English were excluded. Additional articles of interest were identified from the references listings of reviewed articles. Species of *Providencia* were included in this review if the isolate test revealed resistance to any of the carbapenem agents (doripenem, ertapenem, imipenem, or meropenem) or if testing demonstrated carbapenemase production through a phenotypic or molecular assay. Twenty-nine publications met our search criteria and are the subject of this review.

Patient characteristics {#sec3}
=======================

Eighty cases of carbapenem-resistant *Providencia* were described in 29 reports ([Table 1](#tbl1){ref-type="table"}). All studies were descriptive. There were no reports that included a case--control component. The first case of carbapenem-resistant *Providencia* was reported from Japan in 2003 [@bib14]. Carbapenem-resistant *Providencia* was detected in other countries: Afghanistan, Algeria, Argentina, Brazil, Bulgaria, Canada, China, Ecuador, Greece, India, Israel, Italy, Mexico, Nepal, Pakistan, Portugal, South Africa, South Korea, United Kingdom and United States. Carbapenem resistance was discovered in only two *Providencia* species: *P. stuartii* (39 cases were described in 11 reports) and *P. rettgeri* (41 cases were described in 18 reports). Carbapenem-resistant *Providencia* species usually infect adult immunocompromised patients; they were not reported in paediatric patients. The mean age ± SD of the patients was 50.90 ± 18.63 years. Twenty-eight subjects were male, 20 female and gender not specified in 32. Carbapenem-resistant *Providencia* species were isolated from urine (*n* = 32 cases), bloodstream (*n* = 20), respiratory tract sites (*n* = 7), catheter tip (*n* = 3), soft tissue (*n* = 3), pus (*n* = 2), stool (*n* = 2) and bone (*n* = 1). Carbapenem-resistant *Providencia* was recovered from rectal swab in one case report [@bib15]. The site of isolation of carbapenem-resistant *Providencia* was not mentioned in nine instances. Four outbreaks of carbapenem-resistant *Providencia* were reported in the literature [@bib5], [@bib11], [@bib16], [@bib17]; three were caused by carbapenem-resistant *P. stuartii* (CRPS) and one was linked to carbapenem-resistant *P. rettgeri* (CRPR). All the outbreaks occurred in intensive care units (ICUs).Table 1Clinical and demographic characteristics of cases of infection or colonization with carbapenem-resistant *Providencia*Table 1Case no.ReferenceLocationSpeciesYear of isolationSexAge (years)ComorbiditiesSite of isolationAntimicrobial\
therapyPrior antimicrobial therapyMechanism of carbapenem resistanceOutcome15Brazil*P. stuartii*2008M41NRUrineNoneCeftriaxone, ciprofloxacin,\
gentamicinDerepression of\
chromosomally encoded AmpC and ESBL productionDied2F54NRBloodPiperacillin/tazobactam\
plus meropenemCefepime, imipenem, polymyxin BDischarged3M14NRSurgical woundImipenem plus amikacinImipenemDischarged4F52NRCentral venous\
catheterNone for carbapenem-resistant *Providencia stuartii*Cefepime, imipenemDied5F46NRTracheal aspirateLevofloxacinNoneDischarged611Greece*P. stuartii*December 2012 - March 2013FNRNRUrineNRAll the patients\
received several antimicrobial agents (β-lactams,\
quinolones and aminoglycosides) before isolation\
of *P. stuartii,* three received\
colistin and received tigecyclineVIM-1Discharged7FNRNRUrineNRDischarged8M54NRCatheter\
tipMeropenemDied9M27NRBloodMeropenemDied10F73NRBloodMeropenemDied11MNRNRBloodNRDischarged1213Canada*P. stuartii*NRM65Infected\
sacral ulcerUrineDid not receive antimicrobial\
therapy; it was considered colonizationCefazolin, metronidazole, tigecyclineNDM-1Discharged1315Israel*P. rettgeri*2011M74Diabetes, HTNRectal swabNRNRNDM-1NR1416South Africa*P. rettgeri*November 2014 - January\
2015.F26RI on dialysis, respiratory\
Infection, HIVUrineNRNRNRTransferred to high-care unit15F32RI on dialysis, HIVUrineNRNRNRDischarged16M40RI on dialysisUrineNRNRNRTransferred to renal unit17F33RI on dialysis, polytrauma, HIVTissueNRNRNRDied1817Greece*P. stuartii*2011M74Mediastinal tumourBloodPiperacillin/tazobactam plus amikacinNRVIM-1Died19M66CABG, AVR, strokeUrineNRSurvived20M75PancreatitisBloodNRDied21F34Multiple traumaBloodNRSurvived22F67ALS, septic shockBloodNRDied23F63Malignancy, sepsisBloodNRDied24F47Cardiac arrest, pneumoniaUrineNRSurvived25M53StrokeBloodNRDied26F54Brain haemorrhageBloodNRSurvived27M60StrokeUrineNRSurvived28M84AAA repairUrineNRDied29M25Multiple traumaBloodNRSurvived30F75Osteomyelitis, MOFBloodNRDied31M56TTPBloodNRSurvived32M20Multiple traumaUrineNRSurvived3325Afghanistan*P. stuartii*2011NRNRSevere burns, inhalational\
injuryBloodLevofloxacin plus piperacillin/tazobactamPatient received broad-spectrum antibiotics but were not reportedNDM-1Died3426Portugal*P. stuartii*NRM88Enterocutaneous fistulaUrineNRNRNDM-1NR3527Argentina*P. rettgeri*2013M54Vascular diseaseCatheterDid not receive antimicrobial\
therapy; it was considered colonizationNRNDM-1Discharged36M56Terminal prostate cancerUrineAmikacinNRDied3728Italy*P. stuartii*Between May 2011 and April 2014NRNRNRNRNRNRNDMNR3818Brazil*P. rettgeri*2015M55Diabetes, HTN, osteomyelitisBoneCeftriaxone plus clindamycinCiprofloxacin, clindamycin, ceftriaxoneNDMDischarged3922Mexico*P. rettgeri*2012M22NRUrineNRNRNDM-1NR40M16NRUrineNRNRNR41F50NRUrineNRNRNR42F53NRUrineNRNRNR4329Israel*P. rettgeri*2011NRNRNRBloodNRNRNDM-1NR442011NRNRNRBloodNRNRNR452011NRNRNRBloodNRNRNR462008NRNRNRPusNRNRNR472011NRNRNRBloodNRNRNR4830Mexico*P. rettgeri*2015NRNRNRNRNRNRNDM-1, IMPNR4924USA*P. rettgeri*Between 2011 and 2013NRNRHistory of ankle fractureUrineNRNRNDM-1NR5019Brazil*P. rettgeri*2013MNRDiabetes, PVDTissueNRCiprofloxacin, amoxicillin/clavulanateNDM-1Discharged5131India*P. rettgeri*2014NRNRNRNRNRNRNDMNR5232China*P. rettgeri*2012NRNRNRUrineNRNRNDM-1NR5333Nepal*P. rettgeri*2012NRNRSSIPusNRNRNDM-1NR54NRNRNLRTISputumNRNRNDM-1NR55NRNRNLRTISputumNRNROXA-72NR56NRNRNLRTISputumNRNRNDM-1NR5734Canada*P. rettgeri*2010FNRNRUrineNRNRNDM-1NR5820Greece*P. stuartii*2011F45SAHBronchial secretionsMeropenem plus ciprofloxacinMeropenem, colistinVIM-1NR59M72Severe diffuse cerebral ischaemiaUrineIt\
was considered colonizationColistinNR60M42Burn injuriesBronchial\
secretionsIt\
was considered colonizationColistin, tigecyclineSurvived6137Algeria*P. stuartii*2008FNRPEUrineCefotaximeNRVIM-19Died6221Brazil*P. stuartii*2011M52Chronic RI, respiratory failureUrineNoneImipenem, polymyxinKPC-2Discharged6338Brazil*P. stuartii*Between 2009 and 2011NRNRNRNRNRNRKPC-2NR64NRNRNRNRNRNRNR65NRNRNRNRNRNRNR66NRNRNRNRNRNRNR6739Japan*P. rettgeri*2002NRNRNRUrineNRNRIMP-1NR68NRNRNRUrineNRNRNR69NRNRNRUrineNRNRNR70NRNRNRUrineNRNRNR71NRNRNRUrineNRNRNR72NRNRNRUrineNRNRNR73NRNRNRSputumNRNRNR74NRNRNRBloodNRNRNR7514Japan*P. rettgeri*Between January 2001 and December 2002NRNRNRNRNRNRIMP-1NR76NRNRNRNRNRNRNR7735Pakistan*P. rettgeri*Between 16 August and 29 September 2010NRNRNRStoolNRNRNDM-1NR78NRNRNRStoolNRNRNR7936Bulgaria*P. rettgeri*Between October 2013 and November 2014NRNRNRUrineNRNRNDM-1NR8023Ecuador*P. rettgeri*December 2014M49MIUrineMeropenem plus vancomycin plus\
tigecyclineCiprofloxacin, fluconazoleNDM-1Discharged[^1]

Nine of 29 reports mentioned whether or not the patients received prior antimicrobial therapy [@bib5], [@bib11], [@bib13], [@bib15], [@bib18], [@bib19], [@bib20], [@bib21]; all patients in the nine reports received antibiotics before detection of carbapenem-resistant *Providencia* species except one. In one outbreak of CRPS [@bib5], the elevated polymyxin B consumption in that ICU, because of high rates of *Pseudomonas aeruginosa* and *A. baumannii,* might be the cause of the emergence of CRPS. One patient with CRPS in this outbreak had received prior therapy with polymyxin before CRPS detection. Four patients with CRPS received colistin before the isolation of CRPS in two reports [@bib20], [@bib21]. Six critically ill patients were infected with a CRPS isolate in one outbreak in Greece [@bib11], and three received prior therapy with colistin. Three patients received prior tigecycline therapy before the isolation of CRPS [@bib11], [@bib13], [@bib20].

Length of hospitalization before isolation of carbapenem-resistant *Providencia* was rarely reported. However, prolonged hospitalization before isolation of carbapenem-resistant *Providencia* was mentioned in four reports [@bib11], [@bib17], [@bib22], [@bib23]. Prolonged hospitalization ranging from 24 to 106 days before isolation of CRPS was present in one outbreak [@bib11]. In another report [@bib17], the median length of ICU stay was 39, days while acquisition of CRPS occurred in a median of 16 days after ICU admission.

Regarding CRPR, the average time to positive urine cultures for CRPR was 29 days (range, 12--68 days) in one report [@bib22]. In another report [@bib23], the length of hospital stay was 68 days while acquisition of CRPR occurred 52 days after ICU admission. Common equipment such as dialysis machines might facilitate the spread of carbapenem-resistant *Providencia.* In one outbreak of CRPR in South Africa [@bib16], all patients with CRPR were on dialysis; dialysis machines could be the source of CRPR in this outbreak. Three patients were HIV positive, which indicates that immunocompromised patients are more susceptible to CRPR infections. It is worth mentioning that many patients with carbapenem-resistant *Providencia* had urinary catheters [@bib13], [@bib15], [@bib16], [@bib17], [@bib24].

Mechanisms of carbapenem resistance {#sec4}
===================================

New Delhi metallo-β-lactamase 1 (NDM-1) is the most common resistance mechanism to carbapenems in *Providencia* species; it has been increasingly detected among CRPS and CRPR in several countries [@bib13], [@bib15], [@bib18], [@bib19], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36]. Production of VIM-1 metallo-β-lactamase was responsible for carbapenem resistance in *P. stuartii* in two cases and one outbreak [@bib11], [@bib17], [@bib20]. VIM-19 β-lactamase was detected in one case of CRPS associated urinary tract infection [@bib37]. KPC-2 was recovered from CRPS isolates in Brazil [@bib21], [@bib38]. OXA-72 carbapenemase was isolated from *P. rettgeri* in Nepal [@bib33]. While metallo-β-lactamase IMP-1 was detected in CRPR isolates in Japan [@bib14], [@bib39] and one isolate of CRPR was found to produce NDM-1 as well [@bib30], to our knowledge, this is the only reported *Providencia* isolate to date that produced two carbapenemases. Two reports described carbapenemase production in *Providencia,* but they did not mention the species [@bib12], [@bib40]; one report described VIM-2 production in three isolates of *Providencia* in South Korea [@bib12], while the second report described NDM production in three isolates of *Providencia* in the United Kingdom [@bib40].

In one outbreak of CRPS [@bib5], the carbapenem-resistant phenotype was explained by AmpC hyperproduction and extended-spectrum β-lactamase production (CTX-M-2); hyperproduction of AmpC was due to derepressed chromosomally encoded AmpC. Carbapenem resistance in this outbreak probably occurred by of the following mechanisms: modification of the penicillin-binding proteins, conformational change in outer membrane protein or efflux-pump expression. These were not analyzed in this report. This is the first report of the emergence of carbapenem resistance in *Providencia* species due to noncarbapenemase mechanism.

Treatment {#sec5}
=========

Like other bacterial infections, treatment of carbapenem-resistant *Providencia* should depend on the susceptibility of isolates to antibiotics. In addition, the duration of treatment will be dependent on the daily clinical assessment of the treating physician and the microbiologic response to antimicrobial agents. Treatment of carbapenem-resistant *Providencia* was described in nine reports [@bib5], [@bib11], [@bib17], [@bib18], [@bib20], [@bib23], [@bib25], [@bib27], [@bib37]. Because extended infusion of high-dose meropenem (2 g every 8 hours provided via intravenous infusion over 3 hours) is an effective strategy for treating carbapenemase-producing *Enterobacteriaceae* [@bib41], it was part of the antibiotic regimens of many cases of infection with carbapenem-resistant *Providencia* described in the literature. Zavascki *et al.* [@bib5] described the treatment of three of five patients who were infected with CRPS in one outbreak; one patient with bloodstream infection was treated with a combination regimen of high-dose piperacillin/tazobactam (4.5 g every 6 hours) and high-dose extended-infusion meropenem (2 g every 8 hours in a 3-hour infusion); a second patient was treated with amikacin 1 g every 24 hours in combination with imipenem 500 mg every 6 hours for a relatively mild surgical wound infection; and a third patient received levofloxacin (the dose was not reported). The three patients had good outcomes and were discharged from the hospital.

Tshisevhe *et al.* [@bib16] described the treatment of four patients who had urinary tract infections resulting from CRPR. The four patients received carbapenem therapy (drug and dose were not mentioned). Three patients survived and were transferred to home, a high-care unit or a renal unit. Only one patient died; the cause of death was not described in this outbreak. Oikonomou *et al.* [@bib11] reported the treatment of a CRPS isolate that caused infection in six critically ill patients; the *P. stuartii* isolates retained some susceptibility to doripenem and meropenem. Three of six patients (the three had bloodstream infection) were treated with meropenem by prolonged infusion in this outbreak; these three patients died.

Antibiotic synergy tests were proven to be effective in achieving microbiologic eradication in patients infected with CRPS [@bib17]. Douka *et al.* [@bib17] reported one outbreak of CRPS; all isolates had identical susceptibility, patterns with MICs ≥ 16 g/mL to meropenem and imipenem. An antibiotic synergy test was carried out by Etest according to the Clinical and Laboratory Standards Institute guidelines. The most effective combination *in vitro* was piperacillin/tazobactam with amikacin for all the *P. stuartii* isolates. All patients were treated with piperacillin/tazobactam (4.5 g every 8 hours) plus amikacin (1 g every 24 hours) according to the *in vitro* synergy, resulting in microbiologic eradication in all patients involved. However, seven patients died during their hospitalization. Third-generation cephalosporins were used to treat two cases of CRPS [@bib20], [@bib37]. One case of CRPS, in a patient with severe burns and inhalational injury, was treated with levofloxacin and piperacillin/tazobactam; the patient died from complications of severe injuries and central nervous system infection 12 days after injury [@bib25].

Infection control measures {#sec6}
==========================

Stringent infection control practices are important in preventing the spread of carbapenem-resistant *Providencia* species [@bib5], [@bib16], [@bib17], [@bib20], [@bib29]. Any new cases of carbapenem-resistant *Providencia* species in a healthcare facility should promptly draw the attention of the infection control teams. Isolation of patients infected or colonized with carbapenem-resistant *Providencia* species is indispensable. All patients should be under contact precautions. Exclusive medical and nursing equipment for each patient is recommended as well. Thorough sterilization and cleaning of medical equipment like dialysis machines is of paramount importance in the prevention of bacterial contamination and infection [@bib16]. Education of healthcare personnel plays a pivotal role in controlling carbapenem-resistant *Providencia* species--related outbreaks. Hand hygiene practice must be repeated to healthcare personnel, as proper hygienic practice is important in the prevention of bacterial infections in any healthcare facility [@bib16], [@bib17]. One report described four CRPR clinical isolates [@bib22]; a possible epidemiologic link between the patients was a surgical resident involved in the care of the four patients.

Zavascki *et al.* [@bib5] described the infection control measures that were applied to an outbreak of CRPS; private rooms were used to isolate all patients with CRPS. All patients were under contact precautions, including the use of gloves and gowns by any healthcare professional involved in patient treatment. Medical and nursing equipment were restricted for each patient. A strict environmental cleaning policy for rooms and objects that might have contacted colonized patients was applied. The outbreak was terminated after a 40-month period; no additional CRPS cases were detected. If isolating the patients with MDR microorganisms is not feasible, placing the patients in one area of any unit can prevent the further spread of highly MDR Gram-negative bacteria [@bib42]. Identifying and eradicating the outbreak source is essential. In the CRPR outbreak that was described earlier [@bib16], dialysis machines might have been the source. Healthcare providers should thus pay attention when using common equipment. A point prevalence surveillance of colonization must be performed on a regular basis for early identification of equipment and environmental contamination.

Conclusion {#sec7}
==========

Infections with carbapenem-resistant *Providencia* species greatly affect patient morbidity, mortality and treatment. To our knowledge, this is the first review of the literature about carbapenem-resistant *Providencia* species. Usually carbapenem-resistant *Providencia* species are recovered from adult, critically ill and/or immunocompromised patients. Carbapenemase production is the main mechanism of carbapenem resistance in *Providencia* species; the most common isolated carbapenemase is NDM-1. Treatment of carbapenem-resistant *Providencia* should depend on the susceptibility of isolates to antibiotics. Extended infusion of high-dose meropenem is usually part of the antibiotic regimen. Finally, stringent infection control practices are important in preventing the spread of carbapenem-resistant *Providencia* species.

Conflict of interest {#sec8}
====================

None declared.

[^1]: AAA, abdominal aortic aneurysm; ALS, amyotrophic lateral sclerosis; AVR, aortic valve replacement; CABG, coronary artery bypass graft; HTN, hypertension; ICU, intensive care unit; MI, myocardial infarction; MOF, multiple organ failure; NLRTI, nosocomial lower respiratory tract infection; NR, not reported; PE, pulmonary embolism; PVD, peripheral vascular disease; RI, renal impairment; SAH, subarachnoid haemorrhage; SSI, surgical site infection; TTP, thrombotic thrombocytopenic purpura.
